SPORE Core B. Pathology and Tissue Resources Core. The Tissue Resources and Molecular Pathology Core will provide routine and innovative tissues and materials, as well as conventional and molecular pathology assistance, essential for achieving the aims of the SPORE projects. Routine materials include tumors and non-malignant lung specimens and tumor cell lines. Over 2,500 well-characterized tumors with annotated clinical data and 200 cell lines have been banked, and over 15,000 aliquots of tumor or cell line pellets, RNA or DNA or paraffin sections are available to SPORE investigators. State-of-art molecular pathology facilities devoted to lung cancer translational research directed by experienced lung cancer molecular pathologists are available.
Our Aim 1 is to collect, process, store, catalog and distribute tissues, cells and blood specimens, both malignant and non-malignant, and relevant clinico-pathologic data, as requested by the various component projects of the SPORE program.
Aim 2 is to develop and utilize innovative or routine tissue and cell resources that will aid in the successful completion of the SPORE program aims. Innovative materials include: a) cell pellets and tissue microarrays (TMAs) and high throughput image analysis of in situ techniques, b) new lung cancer cell lines and lung cancer xenografts made directly from patient specimens, c) new immortalized and non-immortalized human bronchial epithelial cells (HBECs) and 3-dimensional organotypic cultures.
Aim 3 is to perform and interpret tissue-based molecular methodologies in close collaboration with the component projects of the SPORE program to satisfy their approved aims. This includes immunohistochemistry (IHC) information on over 90 lung cancer relevant biomarkers on the TMAs with information stored in an image database and integrated with the clinical annotations.
Aim 4 is to promote collaboration among investigators in this SPORE, other lung cancer SPORES, other investigators in MD Anderson Cancer Center, UT Southwestern Medical Center, and other investigators nationally and internationally pursuing lung cancer relevant research. All of our five projects in this application will utilize CORE materials. Heavy utilization of our routine and innovative materials, and close interactions with the SPORE investigators will greatly aid the successful completion of the aims of our SPORE proposal. The SPORE Tissue Resource Core is designed and has operated as a facility receiving support from several other sources beyond SPORE funding including in a manner non-overlapping with other Cancer Center activities at both MD Anderson and UT Southwestern Medical Centers. This means that SPORE discoveries and data have far reaching beneficial effects across the range of lung cancer research conducted at these two institutions.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Specialized Center (P50)
Project #
5P50CA070907-12
Application #
7921404
Study Section
Special Emphasis Panel (ZCA1)
Project Start
Project End
Budget Start
2009-05-01
Budget End
2010-04-30
Support Year
12
Fiscal Year
2009
Total Cost
$258,436
Indirect Cost
Name
University of Texas Sw Medical Center Dallas
Department
Type
DUNS #
800771545
City
Dallas
State
TX
Country
United States
Zip Code
75390
Ng, Patrick Kwok-Shing; Li, Jun; Jeong, Kang Jin et al. (2018) Systematic Functional Annotation of Somatic Mutations in Cancer. Cancer Cell 33:450-462.e10
Cascone, Tina; Gold, Kathryn A; Swisher, Stephen G et al. (2018) Induction Cisplatin Docetaxel Followed by Surgery and Erlotinib in Non-Small Cell Lung Cancer. Ann Thorac Surg 105:418-424
Kim, Wanil; Shay, Jerry W (2018) Long-range telomere regulation of gene expression: Telomere looping and telomere position effect over long distances (TPE-OLD). Differentiation 99:1-9
Wang, Min; Abrams, Zachary B; Kornblau, Steven M et al. (2018) Thresher: determining the number of clusters while removing outliers. BMC Bioinformatics 19:9
Sinicropi-Yao, Sara L; Amann, Joseph M; Lopez, David Lopez Y et al. (2018) Co-Expression Analysis Reveals Mechanisms Underlying the Varied Roles of NOTCH1 in NSCLC. J Thorac Oncol :
Le, Xiuning; Puri, Sonam; Negrao, Marcelo V et al. (2018) Landscape of EGFR-Dependent and -Independent Resistance Mechanisms to Osimertinib and Continuation Therapy Beyond Progression in EGFR-Mutant NSCLC. Clin Cancer Res 24:6195-6203
Wang, Shidan; Chen, Alyssa; Yang, Lin et al. (2018) Comprehensive analysis of lung cancer pathology images to discover tumor shape and boundary features that predict survival outcome. Sci Rep 8:10393
Gomez, Daniel Richard; Byers, Lauren Averett; Nilsson, Monique et al. (2018) Integrative proteomic and transcriptomic analysis provides evidence for TrkB (NTRK2) as a therapeutic target in combination with tyrosine kinase inhibitors for non-small cell lung cancer. Oncotarget 9:14268-14284
Parra, Edwin R; Villalobos, Pamela; Mino, Barbara et al. (2018) Comparison of Different Antibody Clones for Immunohistochemistry Detection of Programmed Cell Death Ligand 1 (PD-L1) on Non-Small Cell Lung Carcinoma. Appl Immunohistochem Mol Morphol 26:83-93
Yamauchi, Mitsuo; Barker, Thomas H; Gibbons, Don L et al. (2018) The fibrotic tumor stroma. J Clin Invest 128:16-25

Showing the most recent 10 out of 1059 publications